Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of Internal Medicine

• Publication date

  2018-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/L17-0702PMID 29554680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opening the Book on Maintenance of Certification

  2018cited by this paper
• Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.

  2017cited by this paper
• Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.

  2017cited by this paper
• Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice

  2016cited by this paper
• Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy

  2015cited by this paper
• Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen‐deprivation therapy: a randomised controlled trial

  2015cited by this paper
• The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review

  2015cited by this paper
• Bisphosphonate prescriptions in men with androgen deprivation therapy use.

  2014cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans‐Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer

  2014influential reference
• Skeletal response to resistance and impact training in prostate cancer survivors.

  2014cited by this paper
• RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients

  2013influential reference
• Task Force Report : Bone Health in Cancer Care

  2013cited by this paper
• Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases

  2013cited by this paper
• Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.

  2013cited by this paper
• Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

  2013cited by this paper
• NCCN Task Force Report: Bone Health In Cancer Care.

  2013cited by this paper
• Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.

  2012cited by this paper
• Osteoporosis imaging: state of the art and advanced imaging.

  2012cited by this paper
• Group Exercise versus Personal Training for Prostate Cancer Patients: A Pilot Randomized Trial

  2012cited by this paper
• Screening for osteoporosis in men receiving androgen deprivation therapy.

  2012cited by this paper
• The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer

  2012cited by this paper
• Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

  2012cited by this paper
• Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

  2011cited by this paper
• Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.

  2011cited by this paper
• Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

  2010cited by this paper
• Conducting Meta-Analyses in R with the metafor Package

  2010cited by this paper
• Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

  2010influential reference
• Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

  2010cited by this paper
• Long term zoledronic acid during androgen blockade for prostate cancer.

  2010cited by this paper
• Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

  2009cited by this paper
• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

  2009cited by this paper
• Management of decreased bone mineral density in men starting androgen‐deprivation therapy for prostate cancer

  2009cited by this paper
• Prevention of Bone Mineral Loss by Zoledronic Acid in Men with Prostate Carcinoma Receiving Androgen Deprivation Therapy: A Prospective Randomized Trial in an Indian Population

  2008cited by this paper
• Assessing Risk of Bias in Included Studies

  2008cited by this paper
• Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.

  2008cited by this paper
• FRAX™ and the assessment of fracture probability in men and women from the UK

  2008cited by this paper
• The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

  2007influential reference
• Bmc Medical Research Methodology Open Access Development of Amstar: a Measurement Tool to Assess the Methodological Quality of Systematic Reviews

  2007cited by this paper
• Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open‐label controlled study

  2007cited by this paper
• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  2007cited by this paper
• Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid

  2007cited by this paper
• Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?

  2006cited by this paper
• Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

  2006cited by this paper
• Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530]

  2005cited by this paper
• Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer

  2005cited by this paper
• Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

  2004cited by this paper
• Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study

  2004cited by this paper
• Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

  2004cited by this paper
• Skeletal fractures negatively correlate with overall survival in men with prostate cancer.

  2002cited by this paper
• Low bone mineral density in hormone‐naïve men with prostate carcinoma

  2001cited by this paper
• Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor

  2001cited by this paper
• Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

  2001cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study

  1998cited by this paper
• What is a vertebral fracture?

  1996cited by this paper

• The Effects of Bone‐Remodeling Therapy on Survival, Pain, and Skeletal Related Events in the Setting of Renal Cell Carcinoma With Bone Metastases: A Multicenter Investigation From a Large Global Health Research Network (TriNetX)

  2026cites this paper
• Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review

  2025cites this paper
• Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

  2024cites this paper
• Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

  2023cites this paper
• Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion

  2020cites this paper
• Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm

  2019cites this paper
• Management of bone health in patients with cancer: a survey of specialist nurses

  2019cites this paper
• Maintaining Bone Health During Hormonal Therapy for Prostate Cancer

  2017cites this paper